Results 181 to 190 of about 74,867 (310)

Levodopa Efficacy and GLP‐1 Receptor Agonists

Movement Disorders Clinical Practice, EarlyView.
Catherine Martinez, Christine Girges, Thomas Foltynie, Anne‐Marie Wills   +3 more
wiley   +1 more source

Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo, Filipa Sofia Simas, Angela Ghiletchi, João Oliveira Torres, José Silva‐Nunes   +4 more
wiley   +1 more source

Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression. [PDF]

Diabetes Obes Metab
Tsakiridis EE, Steinberg GR.
europepmc   +1 more source

Reduced‐Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate whether reduced‐frequency dosing of GLP1 receptor agonists maintains weight loss, body composition, and metabolic syndrome improvements following successful initial treatment with standard weekly therapy. Methods This retrospective case series included 30 adults who achieved weight plateau while on weekly
Michelle Wong, Ash Wu, Pawanjot K. Garhe, Mitch Biermann   +3 more
wiley   +1 more source

Surgery for metabolic liver disease [PDF]

, 1986
Starzl, TE
core  

Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control. [PDF]

Rambam Maimonides Med J
Bonga KN, Padhan M.
europepmc   +1 more source

Glucagon receptor (GCGR) [PDF]

Science-Business eXchange, 2009
openaire   +1 more source

Beyond BMI: The Impact of the New Lancet Commission Diagnostic Criteria on Prevalence of Obesity in the United States

Obesity, EarlyView.
ABSTRACT Objective This study compared population characteristics and overall US prevalence of obesity over time using the BMI criteria and the 2025 Lancet Commission criteria (i.e., the Excess Adiposity criteria). Methods We analyzed data from 58,053 adults aged ≥ 20 years in the National Health and Nutrition Examination Survey from 1999 to 2023.
Jennifer H. Hwang, Neda Laiteerapong
wiley   +1 more source

The anti-cachectic effect of fatty acids [PDF]

, 1998
Aderka, Barber, Brennan, Cangiano, Espat, Evans, Fearon, Grunfeld, Gullo, Holian, Holroyde, James A. Ross, Kenneth C. H. Fearon, Kurzrock, Langstein, Lipman, Matthew D. Barber, Mcdevitt, Melville, Michie, Ng, Nixon, O'Riordain, Reeds, Roubenoff, Shaw, Speizer, Stames, Sumida, Wigmore, Wigmore, Yasumoto   +31 more
core   +2 more sources

Gut Peptide Alterations in Type 2 Diabetes and Obesity: A Narrative Review. [PDF]

Curr Obes Rep
Tzeravini E, Simati S, Anastasiou IA, Dalamaga M, Kokkinos A.   +4 more
europepmc   +1 more source